USPTO serial 97703809
CANCER ZERO
Reviewed by CopyMark Law Group
Status 734Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- JANSON, ANDREW KYLE
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with CANCER ZERO?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $947*
Plus Government fees of $450
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
New York, NY, US
New York, NY, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Mark A. Jansen
Mark A. Jansen FENWICK & WEST LLP801 CALIFORNIA STREETMOUNTAIN VIEW, CA 94041United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations, namely, oncological preparations; reagent, diagnostic and therapeutic preparations for medical use in oncology; targeted medical preparations for use in oncology; pharmaceutical preparations for use in the treatment of cancer and tumors; pharmaceutical and medicinal preparations for the treatment of cancer and oncological conditions; pharmaceutical and biological preparations for use in immunotherapies to improve immune system function; pharmaceutical and biological preparations combining immunotherapies and chemotherapies for treatments in the field of oncology; medical and veterinary preparations for the delivery of compounds to the body for the treatment and prevention of immunological and oncological diseases and disorders; pharmaceutical and biological preparations comprised of modified t cells used for multiple modes of treatment against tumor resistance and immunosuppression; pharmaceuticals in the nature of cell therapeutics for the treatment and prevention of cancer; engineered cell therapies, namely, engineered T cells, immune cells, and antibodies for the treatment and prevention of cancer | ACTIVE | — |
| 042 | Research, development, and evaluation of new products; pharmaceutical, medicine, and vaccine research and development services; technical research in the field of pharmaceutical studies; laboratory analysis and research into new drugs and pharmaceutical products; development of scientific measuring and testing methods in the field of oncology; design, development, research, and conducting clinical trials for others in connection with drugs, pharmaceuticals, and cellular therapies for the treatment and/or prevention of cancer; research and development services in the fields of oncology, immunotherapy, chemotherapy and combination therapies for the treatment of cancer and tumors; providing medical research information in the fields of oncology, immunotherapy, chemotherapy and combination therapies; scientific advisory services, namely, providing scientific information, advice and consultancy in the field of oncology; research and development in the field of bioengineering and genetic engineering; Research and development of treatments and therapies in the field of oncology; Research and development of pharmaceuticals for the treatment and prevention of cancer, autoimmune, inflammatory, and infectious diseases and disorders; Scientific research for medical purposes in the field of cancer, autoimmune, inflammatory, and infectious diseases and disorders; Molecular, cellular, and genetic research and development; Development of processes and methods for the manufacturing and engineering of cells and molecules; development of therapeutics and treatments for the prevention of cancer, autoimmune, inflammatory, genetic and infectious diseases and disorders; Development of diagnostic medical measuring and testing methods in the field of cancer therapy and treatment | ACTIVE | — |
| 044 | Medical services; Providing health information; Providing health information in the field of bioengineering and genetic engineering; Providing health information in the field of autoimmune, inflammatory and infectious diseases and disorders, cancer prevention and treatment; Medical diagnosis and treatment of cancer, autoimmune, inflammatory, and infectious diseases and disorders | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 25, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 25, 2026 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Sep 25, 2026 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Aug 13, 2026 | EXT5 | SOU EXTENSION 5 FILED | — |
| Aug 13, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 10, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Mar 9, 2026 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Mar 9, 2026 | EXT4 | SOU EXTENSION 4 FILED | — |
| Mar 9, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 16, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jul 15, 2025 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Jul 15, 2025 | EXT3 | SOU EXTENSION 3 FILED | — |
| Jul 15, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 11, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Mar 11, 2025 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Mar 11, 2025 | EXT2 | SOU EXTENSION 2 FILED | — |
| Mar 11, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 9, 2024 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 9, 2024 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Sep 9, 2024 | EXT1 | SOU EXTENSION 1 FILED | — |
| Sep 9, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 12, 2024 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jan 16, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 16, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 27, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 13, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 12, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 11, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 11, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 23, 2023 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 23, 2023 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 23, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 23, 2023 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Oct 3, 2023 | PBCR | WITHDRAWN FROM PUB - OG REVIEW QUERY | — |
| Sep 19, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 19, 2023 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Sep 19, 2023 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Sep 19, 2023 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Sep 19, 2023 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Sep 12, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 3, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 8, 2022 | NWAP | NEW APPLICATION ENTERED | — |